McClure Erin A, Tomko Rachel L, Salazar Claudia A, Akbar Saima A, Squeglia Lindsay M, Herrmann Evan, Carpenter Matthew J, Peters Erica N
Department of Psychiatry and Behavioral Sciences.
Battelle Public Health Center for Tobacco Research.
Exp Clin Psychopharmacol. 2019 Jun;27(3):265-275. doi: 10.1037/pha0000244. Epub 2018 Dec 17.
The co-use of tobacco and cannabis is a common practice worldwide and carries with it substantial public health burden. Few interventions exist that target both substances and little is known about quit interest, treatment preferences, and drug substitution during past cessation attempts, which is critical to guide the development of treatment strategies. The goal of this study was to provide descriptive information regarding quit interest, treatment preferences, and perceived drug substitution among adult (age 18 +) cannabis-tobacco co-users. Participants ( = 282) from two independent survey samples (recruited from Amazon Mechanical Turk) from across the United States were combined. Among all participants, 57% were female, 79% were White, and average age was 33.31 ( = 9.54) years old. Approximately 80% had tried to quit smoking cigarettes at least once, while 40% had tried to quit using cannabis at least once. Of those who tried to quit, 50% self-reported a perceived increase in their cannabis use during tobacco cessation and 62% self-reported a perceived increase in their tobacco use during cannabis cessation. Average quit interest (10-point scale) for cannabis was 2.39 ( = 2.35) and for tobacco was 7.07 ( = 2.90). Results of this study suggest that tobacco use should be addressed among cannabis-tobacco co-users, but interventions should consider lack of interest in cannabis cessation. Reduction-based strategies for cannabis use appear to be more acceptable to this nontreatment-seeking, co-using population. Drug substitution during quit attempts for one substance should be further explored as an important treatment consideration. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
烟草和大麻共同使用在全球范围内很常见,并带来了巨大的公共卫生负担。针对这两种物质的干预措施很少,对于过去戒烟尝试期间的戒烟意愿、治疗偏好和药物替代知之甚少,而这对于指导治疗策略的制定至关重要。本研究的目的是提供有关成年(18岁及以上)大麻-烟草共同使用者的戒烟意愿、治疗偏好和感知药物替代的描述性信息。来自美国各地的两个独立调查样本(从亚马逊土耳其机器人招募)的参与者(n = 282)被合并。在所有参与者中,57%为女性,79%为白人,平均年龄为33.31(SD = 9.54)岁。约80%的人至少尝试过一次戒烟,而40%的人至少尝试过一次戒掉大麻。在那些尝试戒烟的人中,50%自我报告在戒烟期间感知到大麻使用增加,62%自我报告在戒大麻期间感知到烟草使用增加。大麻的平均戒烟意愿(10分制)为2.39(SD = 2.35),烟草为7.07(SD = 2.90)。本研究结果表明,在大麻-烟草共同使用者中应解决烟草使用问题,但干预措施应考虑到对戒大麻缺乏兴趣。对于这种不寻求治疗的共同使用人群,减少大麻使用的策略似乎更可接受。作为一个重要的治疗考虑因素,应进一步探索在尝试戒掉一种物质期间的药物替代。(PsycINFO数据库记录(c)2019美国心理学会,保留所有权利)